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Responsible Regulation in Action? 
Responsible Research and Innovation and the European Bank for induced pluripotent Stem Cells 
 
Shawn HE Harmon∗ 
 
Abstract: Ambitions for regenerative medicine remains a strong motivator for healthcare 
research and resource development.  Central to the evolving vision for regenerative 
medicine are stem cells, and now human induced pluripotent stem cells (iPSCs).  Against 
the promissory and technically innovative backdrop of this technology, there has been a 
growing concern for legitimacy and integrity in science and innovation.  This, in turn, has 
encouraged discourses around the idea of ‘responsibility’, and the notion of ‘responsible 
research and innovation’ (RRI), which has gained considerable policy traction in Europe.  
This paper considers the concept of RRI within the context of a specific European research 
project: the European Bank for induced pluripotent Stem Cells (EBiSC).  EBiSC is a resource 
development project – a biobank – that has as its stated aims the establishment of a 
leading European-based bank that will, inter alia, promote wider use of iPSCs and global 
iPSC banking with the ultimate aim of enhancing the health of people.  Specifically, this 
paper considers how EBiSC’s Phase I (2014-2016) governance activities comply with 
expectations that might be distilled from RRI, and what RRI might impose on EBiSC’s post-
Phase II (2017-2019) entity.  In doing so, it offers some guidance on how RRI might be 
operationalised at the project level. 
 
Keywords: European Union; Responsible Research and Innovation; science governance; 
induced pluripotent stem cells; biobanks; EBiSC; values 
 
1. Introduction 
 
Very broadly, ‘regulation’ is meant to be a framework for decision-making that ensures a focused, 
structured, and ongoing attempt at steering conduct.  It is: 
 
the sustained and focused attempt to alter the behaviour of others according to standards 
or goals with the intention of producing a broadly identified outcome or outcomes, which 
may involve mechanisms of standard-setting, information gathering, and behaviour-
modification.1 
 
Given this understanding, regulation typically follows a cycle of ‘direction, detection, and correction’, relying 
on signals that are meant to direct the conduct of regulatees, methods of monitoring the conduct of 
regulatees, and measures aimed at correcting that conduct where there is deviation from established 
standards.2  Further, although ‘responsible regulation’ might start with risk and safety concerns, it does not 
end there; in the context of new technologies and practices, like population biobanking, it involves attention 
to multiple issues, such as how the technology/practice distributes risk and benefit, what social and political 
arrangements are necessary for, and favoured by, the technology/practice, and what the real purposes of 
the technology/practice are.3 
                                                          
∗ Dr Shawn Harmon is a Reader in Law at the University of Edinburgh, School of Law.  He researches primarily in the 
areas of medical law, human rights, and ethics and the arts.  He can be reached at shawn.harmon@ed.ac.uk.  The 
author acknowledges that he has been a Member of EBiSC and a recipient of IMI-JU funding thereunder. 
1  J Black, ‘What is Regulatory Innovation?’ in J Black, M Lodge and M Thatcher (eds.), Regulatory Innovation 
(Cheltenham: Edward Elgar, 2005) 1-X, at 11. 
2  R Brownsword, ‘Responsible Regulation: Prudence, Precaution and Stewardship’ (2011) 62 N Ir Legal Q. 573. 
3  M Lee, ‘Beyond Safety? The Broadening Scope of Risk Regulation’ (2009) 62 Current Legal Problems 242. 
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It has additionally been observed that lawyers often make the mistake of trying to understand the 
governance of the social world through legal instruments.4  However, good governance is often enacted by 
many parties, including those who are themselves governed. Thus, regulatees also construct the governance 
setting applicable to them.  In Europe, the idea of ‘good governance’ of research and innovation is presently 
influenced by the idea of ‘responsibility’, and the notion of ‘responsible research and innovation’ (RRI).  In 
fact, RRI has gained considerable policy traction in Europe.  It was mooted in the Proposal for a Regulation 
Establishing Horizon 2020,5 and then included in the Regulation itself.  Recital 22 of Regulation (EU) No. 
1291/2013 of the European Parliament and of the Council of 11 December 2013 establishing Horizon 2020 
states: 
 
With the aim of deepening the relationship between science and society and reinforcing 
public confidence in science, Horizon 2020 should foster the informed engagement of 
citizens and civil society in research and innovation matters by … developing responsible 
research and innovation agendas that meet citizens’ and civil society’s concerns and 
expectations and by facilitating their participation in Horizon 2020 activities. The engagement 
of citizens and civil society should be coupled with public outreach activities to generate and 
sustain public support for Horizon 2020. [emphasis added] 
 
In Work Programme 2014-2015: Science with and for Society, implemented by Decision C(2015)2453 of 17 
April 2015 of the European Commission (EC), RRI-related projects were included for funding.6 
In this paper, I consider RRI as a regulatory concept that imposes on regulatees obligations 
associated with ‘direction, detection, and correction’.  In doing so, I focus on a specific European research 
project: the European Bank for induced pluripotent Stem Cells (EBiSC).7  Funded by the EC’s Innovative 
Medicines Initiative Joint Undertaking (IMI-JU) with the European Federation of Pharmaceutical Industries 
and Associations (EFPIA), EBiSC is a resource development project – a biobank – that has as its stated aims 
the establishment of a sustainable bank for induced pluripotent stem cells (iPSCs).8  Indeed, it is expected 
that EBiSC will:9 
 
• promote wider use of iPSCs and encourage global iPSC banking with the ultimate aim of enhancing 
the health of people and contributing to the development of the bioeconomy; 
• spearhead Europe in iPSC banking by forging collaborative links internationally; and 
• become a flagship enterprise by setting new technical standards and best practice. 
 
                                                          
4  Brownsword, note 2. 
5  European Commission, Establishing Horizon 2020 – The Framework Programme for Research and Innovation 
(2014-2020), COM(2011) 809 Final. 
6  European Commission, Horizon 2020 Work Programme 2014-2015: Science with and for Society (Revised), EC 
Decision C(2015)2453; European Commission, at http://ec.europa.eu/programmes/horizon2020/en/h2020-
section/responsible-research-innovation [accessed 20 April 2017]. 
7  The EBiSC project has received support from the Innovative Medicines Initiative Joint Undertaking (Agreement 
n° 115582), a scheme whereby the project receives a financial contribution from the European Union's Seventh 
Framework Programme (FP7/2007-2013), and financial and/or in-kind contributions from the European Federation of 
Pharmaceutical Industries and Associations. 
8  iPSCs are tissue or organ-derived cells that have been reprogrammed to an embryonic stem cell-like state by 
being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. A 
key feature of pluripotent stem cells is their ability to be propagated indefinitely whilst maintaining stable properties in 
tissue culture.  See K Takahashi, K Tanabe et al., ‘Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by 
Defined Factors’ (2007) 131 Cell 861. With the advent of iPSCs, research opportunities have expanded dramatically: 
Organization for Economic Cooperation and Development, The Bioeconomy to 2030: Designing a Policy Agenda (Paris: 
OECD, 2009; G Vogel, ‘Cellular Reprogramming: new Technique RiPS Open Stem Cell Field’ (2010) 330 Science 162. 
9  See EBiSC, at http://www.ebisc.org/about-ebisc/the-project.php. 
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This paper considers how EBiSC’s Phase I (2014-2016) governance activities comply with expectations that 
might be distilled from the regulatory concept of RRI, and what RRI might impose on EBiSC’s post-Phase II 
(2017-2019) structures (i.e., its Legacy Entity).  In doing so, it offers some guidance on how this regulatory 
concept might be operationalised at the project (or regulatee) level.  As such, in the second and third 
sections below, I explore the idea of RRI generally, and then what it might impose on those working in the 
research setting, with a view to articulating a framework for evaluating a project like EBiSC.  In the fourth 
section, I apply that framework to EBiSC’s Phase I structures and practices, which were aimed not only at 
founding an efficient and reliable resource, but also a legally and ethically responsible one.  Given the 
ambitions for EBiSC, in the final section I offer a view on what RRI might additionally impose with respect to 
governance of the Legacy Entity in the post-Phase II (2017-2019) period.  I conclude that, if projects like 
EBiSC, which are meant to endure into the future, are to avoid governance failures, and remain legitimate, 
they will need to pay sufficient attention to the matters raised. 
 
2. The Meaning of RRI 
 
RRI evolved out of discussions about research integrity in relation to controversial technologies like 
genomics, synthetic biology, and nanotechnologies,10 and from concerns about the value of science,11 the 
control of technologies in contexts of uncertainty and ignorance,12 and the impact of globalism.13  One of the 
aims was to prevent technological disasters such as have been suffered in the past.14  It should be clear from 
this genesis that RRI is meant to help protect individuals and communities, and to encourage public support 
for science and innovation.  On the latter, RRI is not about instilling trust as a means of assuring the scientific 
undertaking – and one might argue that it is only marginally within the power of protagonists to induce 
feelings of trust in others – but rather about demonstrating to stakeholders the trustworthiness of primary 
actors, and so to encourage relations of trust.15  On the former, RRI is concerned with facilitating the 
internalisation of justice-enhancing characteristics such as autonomy, equity, and democracy.  These are 
particularly pertinent where undertakings are supported by public funds, obtain resources through the 
altruism of others, and aim to serve human wellbeing in contexts where a lack of justice can have harmful 
consequences for actors beyond the immediate undertaking.16 
With respect to a working definition, RRI has been described as advancing the idea of adaptive and 
anticipatory governance (i.e., that it is, at base, oriented towards anticipation, responsiveness, reflexivity, 
and inclusiveness).17  It has also been argued that, like some of the earlier science governance frameworks, 
                                                          
10  B Adam and G Groves, ‘Futures Tended: Care and Future-Oriented Responsibility’ (2011) 31 Bulletin of Science, 
Technology & Society 17-27; R Von Schomberg (ed.), Toward Responsible Research and Innovation in the ICTs and 
Security Technologies Fields (Brussels: European Commission, 2011). 
11  M Kearnes and M Weinroth, A New Mandate? Research Policy in a Technological Society (Durham: DUP, 2011). 
12  D Collingridge, The Social Control of Technology (London: Pinter, 1980). 
13  D Wright, et al., ‘Precaution and Privacy Impact Assessment as Modes towards Risk Governance’ in Von 
Schomberg (ed.), note 10, 83-97. 
14  H Sutcliffe, A Report on Responsible Research and Innovation (2011), at 
https://ec.europa.eu/research/science-society/document_library/pdf_06/rri-report-hilary-sutcliffe_en.pdf [accessed 22 
October 2015]. 
15  O O’Neill, Autonomy and Trust in Bioethics (Cambridge: CUP, 2002); N Manson and O O’Neill, Rethinking 
Informed Consent in Bioethics (Cambridge: CUP, 2007). 
16  It is well known that critical shortfalls in trust and/or perceptions of justice can lead not only to failure of the 
undertaking, but also, as demonstrated by a variety of healthcare and research missteps, to other and very public 
consequences: M Hunter, ‘Medical research under threat after Alder Hey scandal’ (2001) 322 British Medical Journal 
448; M Hansson, ‘Ethics and Biobanks’ (2009) 100 British J Cancer 8; J Higgins, ‘Hospitals in Trouble’ in M Exworthy et al. 
(eds.), Shaping Health Policy (Bristol: Policy Press, 2012) 95. 
17  Von Schomberg, note 10; R Owen and N Goldberg, ‘Responsible Innovation: A Pilot Study with the UK 
Engineering and Physical Sciences Research Council’ (2010) 30 Risk Analysis 1699; R Owen, P Macnaghten and J Stilgoe, 
‘Responsible Research and Innovation: From Science in Society to Science for Society, with Society’ (2012) 39 Science & 
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RRI strives for a more democratic and equitable science/society relationship, one that is deliberative and 
cooperative rather than competitive and bargained.18  Sutcliffe argues that RRI means that science and 
innovation activities must: focus on achieving public goods, particularly sustainable social and environmental 
benefits; be assessed in part on how well they facilitate positive social, ethical, and environmental impacts; 
and integrate ongoing dialogue with communities of interest, including public and non-governmental 
organisations.19  Ultimately, RRI calls for a comprehensive approach to research whereby all stakeholders 
can, at an early stage, develop insight into the consequences of research outcomes, secure knowledge about 
the range of options appropriate to a problem, effectively assess those options and outcomes in terms of 
social needs and moral values, and use this information to design new research, products, and services.20 
RRI now serves as a cross-cutting theme for the EU’s Horizon 2020 Programme for Research and 
Innovation.  Article 12(1) of Regulation (EU) No 1291/2013, states that, in addition to advice and inputs 
provided by independent experts set up by the EC, inputs will be provided from dialogue structures created 
under international science and technology agreements, forward-looking activities, targeted public 
consultations, and transparent and interactive processes that ensure that responsible research and 
innovation is supported.  On its RRI Toolkit Page, the EC states that RRI is about involving society upstream in 
the research process so as to align outcomes with societal values.21  It also states that RRI calls for public 
engagement, open access, gender equality, science education, ethics, and governance.  On its Horizon 2020 
Page, the EC defines RRI as follows: 
 
Responsible research and innovation is an approach that anticipates and assesses 
potential implications and societal expectations with regard to research and innovation, 
with the aim to foster the design of inclusive and sustainable research and innovation. 
 
Responsible Research and Innovation (RRI) implies that societal actors (researchers, 
citizens, policy makers, business, third sector organisations, etc.) work together during the 
whole research and innovation process in order to better align both the process and its 
outcomes with the values, needs and expectations of society.22  
 
The EC goes on to state that RRI necessitates engaging actors in inclusive, participatory practices at all stages 
of research and all levels of governance, from agenda setting, to design and implementation, to evaluation.   
Perceived benefits are articulated as informed and engaged publics, responsible actors and institutions, 
ethically acceptable sustainable research and practices, and solutions to major societal challenges. 
Given the above, it seems clear that RRI should be understood as having two components.  Its first, a 
substantive component, provides a normative foundation for science and innovation.  This includes the idea 
of collective responsibility and collaborative trajectory-formation, the foregrounding and evolutionary 
development of a research ethos or culture, and the explicit imperative that research outcomes tackle 
                                                                                                                                                                                                   
Public Policy 751; B Stahl, ‘Responsible Research and Innovation: The Role of Privacy in an Emerging Framework’ (2013) 
40 Science & Public Policy 708. 
18  M Van Oudheusden, ‘Where are the politics in responsible innovation? European governance, technology 
assessment, and beyond’ (2014) 1 J Responsible Innovation 67. 
19  Sutcliffe, note 14. 
20  EC Expert Group on Dealing with Ethical and Regulatory Challenges of International Biobank Research, 
Biobanks for Europe: A Challenge for Governance (Brussels: EC, 2012); EC Expert Group on the State of the Art in Europe 
on Responsible Research and Innovation, Options for Strengthening Responsible Research and Innovation (Brussels: EC, 
2013). 
21  EU, RRI Toolkit (2017), at https://www.rri-tools.eu/about-rri [accessed 8 March 2017]. 
22  EU, Horizon 2020: Responsible Research and Innovation (2017), at 
http://ec.europa.eu/programmes/horizon2020/en/h2020-section/responsible-research-innovation [accessed 7 March 
2017]. 
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societal challenges, contribute to sustainable development, and exhibit ethical acceptability.23  The second 
component is a procedural component, which demands the construction and maintenance of inclusive and 
discursive decision-making processes aimed at broadening governance participation and expanding 
governance considerations to include anticipation and foresighting.  This understanding of RRI builds on 
earlier scholarship aimed at opening up new and emerging science and technologies to public debate and 
reflection, and on persistent calls for actors and communities of interest to become mutually responsive to 
each other, forming governance partnerships that might better realise the promises being made on behalf of 
new lines of inquiry, techniques, and technologies. 
 
3. The Demands of RRI on Individual Projects 
 
Obviously, RRI imposes obligations on governments, regulators, and funders, for they set social objectives 
and technical targets for innovation (and the funding of same).  And one can already see a range of actions 
that have been taken by these bodies to operationalise the idea of RRI.  For example, the UK’s Engineering 
and Physical Sciences Research Council has begun to reposition itself as a ‘sponsor’ and ‘shaper’ of research, 
and has tried to ensure responsible actions in the face of ignorance, uncertainty and ambiguity,24 recently 
announcing its commitment to an RRI framework.25  Similarly, through the crafting of the call to which EBiSC 
responded, and the vetting of the applications, the IMI has taken into account some of the objectives of RRI, 
ensuring that proposed activities reflect, to the extent possible given scientific objectives and budgets, 
concepts derivative of RRI.26  In this way, the notion of RRI reaches through to researchers and imposes 
obligations on them to shape their activities according to appropriate norms.27 
But what does RRI mean for projects like EBiSC which are primarily instrumental and understood as 
in some way advancing policy positions that have already been determined?  While some of the most 
demanding engagement and anticipatory activities may have already taken place, the central concept of 
‘responsibility’, which is both morally and practically significant, remains an objective that other actors must 
pursue (and achieve) within projects, particularly biobank projects like EBiSC which are expected to continue 
operating beyond the funding period.  Attention to responsibility demands that research activities not only 
be compliant with fundamental human rights (attending to safety and efficacy in the process), but also that 
they incorporate a sufficient level of clarity, attention to standards, accountability, reflection, and 
democracy.28  Indeed, the Nuffield Council on Bioethics has stated that the duty to develop emerging 
biotechnologies in accordance with the public interest and pursuant to a public ethic falls not only on public 
authorities, but also, as a matter of moral responsibility, on firms, groups and individuals.29  It goes on to 
offer some procedural virtues intended to foster a public discourse ethics, including openness and inclusion, 
accountability, public reasoning, candour, enablement, and caution.30 
 From the above definitions, one can distil a number of RRI-sensitive operational expectations 
relevant to an international biobanking undertaking like EBiSC, namely that the biobank will: 
 
i. pursue salutary knowledge and healthcare objectives, and communicate both them and information 
about the operations of the undertaking to the public; 
                                                          
23  For more on this component of RRI, see S Harmon, ‘Responsible Research and Innovation: Function, Form, 
Failings and Contribution to Good Governance of Individual Projects’ in review with the J Responsible Innovation. 
24  R Owen, ‘The UK Engineering and Physical Sciences Research Council’s commitment to a framework for 
responsible innovation’ (2014) 1 J Responsible Innovation 113-117. 
25  EPSRC, Framework for Responsible Innovation, at https://www.epsrc.ac.uk/research/framework/ [accessed 23 
October 2015]. 
26  For more on IMI and its calls, see https://www.imi.europa.eu/content/documents [accessed 27 April 2017]. 
27  Owen et al., note 17. 
28  Ibid; Stahl, note 17. 
29  Nuffield Council on Bioethics, Emerging Biotechnologies: Technology, Choice and the Public Good (London: 
NCOB, 2012), at 67. 
30  Ibid, Ch. 4. 
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ii. approach operational issues (i.e., key scientific and practical demands) in a way that is ethically 
defensible; and 
 
iii. design-in governance elements that make clear responsibilities, recourse for those 
wronged/harmed, and avenues for engagement by stakeholders with regard to changing conditions, 
risks, operational possibilities, etc., bearing in mind the virtues offered by the Nuffield Council on 
Bioethics for ensuring that questions of value and conduct are raised and addressed. 
 
The extent to which the project (and resultant Legacy Entity) reflects these criteria offers some indication 
about the extent to which RRI is being achieved. 
 
4. The RRI Criteria and EBiSC Phase I 
 
EBiSC Phase I (2014-2016) was structured by the Project Agreement (Agreement), the Description of Work 
(DOW), and the documents developed iteratively against the background of the ‘hot start’,31 being the 
Common Information Pamphlet (CIP), the Common Consent Form (CCF), the Material Deposit Agreement 
(MDA), and Access and User Agreements (AUA).32  These documents serve as the primary means of 
structuring EBiSC’s internal activities and external relations and decisional processes. 
 
i. Salutary Health Objectives and Operations Clearly Communicated 
 
The first RRI-alignment criteria is that objectives should be justifiable (i.e., should represent a ‘good 
outcome’), and both objectives and their supporting operations should be made abundantly clear to publics.  
In other words, EBiSC must sufficiently expose its (socially useful and ethically sound) ambitions and 
operations to public scrutiny.  This involves communication of aims and operations, but also a justification of 
same according to values and some defensible sense of public good. 
Human ESCs have proven to be controversial, with concerns revolving around moral, technical and 
political issues.33  Those relating to personhood, dignity and instrumentalisation have been particularly 
divisive.34  Thus, iPSCs were welcomed as a technically promising and less morally troubling route toward 
                                                          
31  Under the ‘hot start’, pre-existing samples and iPSC lines obtained for a range of purposes and under variable 
conditions by different members or associated organisations were brought into the bank, while processes were still 
being designed and new lines were being commissioned.  The idea was that the bank would be ‘open for business’ by 
the end of Phase I: P De Sousa, R Steeg et al., ‘Rapid establishment of the European Bank for induced Pluripotent Stem 
Cells (EBiSC)-the Hot Start experience’ (2017) 20 Stem Cell Research 105. 
32  These forms, and the SOPs they represent, are under constant scrutiny, and are subject to regular revision.  
The versions to which this paper refers were in effect as of 1 November 2016. 
33  For example, there have been persistent expressions of uncertainty about the scope of the term ‘human’, the 
moral status of the embryo, and the appropriate/actual beginning of personhood, and concern around the safety of 
female embryo donors, who are often medicinally super-ovulated to produce sufficient or excess embryos.  The 
justifiability of hESC acquisition, which requires the destruction of early embryos, has resulted in significant controversy 
and made internationally harmonised approaches to hESC impossible.  Similarly, questions have been asked about the 
propriety of investing large sums of finite research resources into expensive technologies that have little potential to 
reach the clinic in the short term, and might, in any event, prove inaccessible to large segments of the population, both 
locally and globally. 
34  For more on the promise and controversies, see S Harmon and A Bruce, ‘Discursive Typologies and Moral 
Values in Stem Cell Politics, Regulation and Commercialisation: Some Preliminary Observations’ (2009) 6 J International 
Biotechnology Law 61 (Part I) and 89 (Part II).  For a discussion of the different regulatory positions relating to hESCs, 
see S Harmon, ‘Semantic, Pedantic or Paradigm Shift? Recruitment, Retention and Property in Modern Population 
Biobanking’ (2008) 16 European J Health Law 27.  The view that such use is contrary to human dignity came before the 
European Court of Justice in Brüstle v Greenpeace eV, Case C-34/10, 18 October 2011, Grand Chamber.  For more on 
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clinical regenerative medicine (and the IMI-JU entertained funding proposals for iPSC-related projects).35 
While EBiSC fails to acknowledge this history, it does identify a number of preclinical uses and 
potential benefits, including:36  
 
• better understandings of the mechanism of cellular reprogramming, factors determining 
pluripotency, and the programmed nature of individual cell fates; 
 
• better understandings of the genetic basis of disease, how individual patients within a given 
diagnosis are different, the development of new medicines as future treatments for those diagnoses, 
and support for clinical understanding of individual patient responses to medicines being tested; 
 
• development of disease-representative cell lines differentiated into relevant tissue types such that 
they can be used in phenotypic screens to identify compounds that cause a desirable change in 
phenotype, thereby offering prospects in symptom or disease modification; 
 
• validation of biochemical pathway targets that have been previously hypothesized as potentially 
disease-modifying, thereby leading to a higher probability of drug efficacy in clinical development; 
 
• identification of individuals’ diseases at the molecular level so that targeted treatments can be 
deployed, a course based on the ability to better stratify into more precise treatment groups those 
patients who have been given a particular diagnosis.; and 
 
• use in pharmacovigilance once medicines have been approved for market, by providing a cell-based 
assay to identify the molecular correlation of individual patient response variations to a given drug.37 
 
And of course, ambitions for this technology being used in a stratified or personalised clinical context remain 
largely intact, though they have been pushed well down the pipeline. 
EBiSC assumes, without explicitly stating, that these potential outcomes are socially useful and 
worthy of investment.  To achieve them, it was felt that a consistent supply of ethically sourced, 
standardised, high-quality iPSC lines is needed, and if potentially crippling inefficiencies are to be avoided, 
such will have to be supplied by internationally networked collaborative banks like EBiSC. Thus, EBiSC self-
describes as a response to increasing researcher demand for quality-controlled, disease-relevant research 
grade iPSC lines.38  With extended funding, EBiSC is expected to become a self-sustaining bank by 2019, 
boasting a catalogue capacity of 10,000 cell lines.  That Legacy Entity will, it is expected, be a centralised 
European not-for-profit iPSC bank providing all qualified users with access to top-quality, scalable, cost-
efficient and customised products from a large online catalogue. 
This general vision for iPSC use in research is articulated in the DOW.39  The Agreement states that 
                                                                                                                                                                                                   
this case, see S Harmon, G Laurie and A Courtney, ‘Dignity, Plurality and Patentability: The Unfinished Story of Brüstle v 
Greenpeace’ (2012) 38 European Law Rev 92. 
35  Though it should be acknowledged that extensive research is required to understand how to use iPSCs safely 
and effectively in the clinical setting, and privacy concerns persist because of the traceability of samples: M Morrison, L 
Moraia and J Steele, ‘Traceability in stem cell research: From participant sample to induced pluripotent stem cell and 
back’ (2016) 11 Regenerative Medicine 73. 
36  EBiSC, Major Applications of iPSC (2017), at https://www.ebisc.org/the-ebisc-catalogue/major-applications-of-
ipsc.php [accessed 27 April 2017]. 
37  And such pharmacovigilance is expected under medicinal products regulation, but it is also rarely effectively or 
systematically pursued: P Fontanarosa, D Rennie et al., ‘Postmarketing Surveillance—Lack of Vigilance, Lack of Trust’ 
(2003) 292 JAMA 2647; P Waller, ‘Getting to grips with the new European Union pharmacovigilance legislation’ (2011) 
20 Pharma & Drug Safety 544. 
38  De Sousa et al., note 31. 
39  DOW, at 8. 
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EBiSC accedes to the ethical framework of FP7, and all existing and future applicable legislation, and will 
refrain from pursuing (under this project) research aimed at human cloning for reproductive purposes, 
modifying the heritable or germline genetic heritage of human beings (through, for example, gene editing 
technologies),40 and creating human embryos solely for research or SC procurement.41  These are important 
commitments, but these documents are not publicly available.  So how are EBiSC’s justifications and 
objective communicated? 
The answer is that they are communicated through direct interactions with Members, through flyers 
distributed, and presentations made, at expert events, and more generally and consistently through EBiSC’s 
website, which is the primary public-facing tool for communication.  It states that EBiSC aims to establish a 
European Bank for iPSCs in support of preclinical research and in response to increasing demands for quality-
controlled, disease-relevant, research-grade iPSC lines, data and cell services.  Its perceived benefits and 
intended scope, together with the general structure of the project are conveyed in the Home, About EBiSC, 
Catalogue, and Partners pages.  Perhaps the most informative communique on the website is the General 
Project Presentation (GPP), which positions iPSCs and EBiSC in the research environment, identifies some 
Phase I milestones and benefits to stakeholders, and defends its aims by claiming that a central resource 
will: 
 
1. define and disseminate best practice for iPSC-based research to donors, clinicians, funders, patients, 
and researchers; 
2. provide confidence in current European practice for iPSC research; 
3. provide a focal point for academics and SME’s for technology innovation; and 
4. enable faster, more cost-effective research.   
 
Of course, the validity of some of EBiSC’s claims and expectations has yet to be proven, and the website is 
undeniably aimed at target communities (e.g., potential depositors and potential users), as demonstrated by 
the range of documents on the Documentation page.  Further, while the GPP is informative, it is not strongly 
foregrounded in the website.  Buried on the Documentation page (where one might rather expect to see the 
CIP, CFF, MDA, and AUA), it probably does not meet the strong signalling/communication function called for 
by RRI.  Ultimately, then, the website conveys the sense of commitment held by the Members together with 
some understanding of the project’s general structure and activities, but the detail required to emphatically 
meet the demands of RRI is absent. 
 
ii. Operational Challenges Ethically Managed 
 
A project of this size and diffusion poses a number of operational challenges, many characterised by 
uncertainty and requiring substantial and sustained support, specialised infrastructure, and technical 
competence.42  While operational challenges will have scientific foundations, they are also undeniably moral 
in nature, and they speak to the ethical grounding of the project.43  For example, ensuring the availability of 
quality lines and associated data, a practical aim grounded in science and technical capabilities, has the 
ethically significant objective of reducing the expense and labour of collecting human material and the need 
                                                          
40  For more on these, see J Doudna and E Charpentier, ‘The New Frontier of Genome Engineering with CRISPR-
Cas9’ (2014) 346 Science 1077, and  J Sugarman, ‘Ethics and Germline Gene Editing’ (2015) 16 EMBO Reports 879. 
41  Agreement, Special Clause 5. 
42  M Turner, S Leslie et al., ‘Toward the Development of a Global Induced Pluripotent Stem Cell Library’ (2013) 13 
Cell Stem Cell 382; G Stacey, J Crook et al., ‘Banking Human Induced Pluripotent Stem Cells: Lessons Learned from 
Embryonic Stem Cells’ (2013) 13 Cell Stem Cell 385. 
43  For more on the dual nature of these challenges and the approach adopted to solving them within EBiSC, see S 
Harmon, ‘Standard-Setting for Regenerative Medicine Research: The Case for the European Bank for Induced 
Pluripotent Stem Cells (EBiSC)’ in J Graham and C Holmes (eds.), Articulating Standards: Translating the Practices of 
Standardizing Health Technologies, forthcoming from UBC Press. 
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to derive cell lines on an individual or project-basis. A failure to manage these operational challenges well 
will undermine the ‘responsibility’ that can be attributed to the project.  In the biobank context, key 
operational challenges are ‘inclusion’, ‘traceability’, ‘distribution’, and ‘capacity-building’.44 
The first operational challenge is inclusion of materials into the bank, which is linked to recruitment 
of donors and consent.  It demands that the bank custodian ensures the provenance of the biological sample 
and associated data.  EBiSC must therefore satisfy itself that the deposited sample was taken with consent 
appropriate to the use intended by the bank, and in compliance with regulatory standards in effect at the 
place of taking.  In short, there must be evidence that those entitled to seek and give consent have acted as 
expected, and that the recruiter has received prior ethical and scientific approval, which includes an 
assurance that it is compliant with its local licensing and/or regulatory requirements with respect to tissue-
handling and use rules.  Additionally, EBiSC must articulate rigorous (scientific) selection criteria for making 
inclusion decisions with respect to samples meant to be expanded into lines, thereby ensuring that all 
products distributed are of suitable and documented scientific quality. 
Given these demands, EBiSC has developed a Common Consent Form (CCF) to be used by its iPSC 
Centres in their recruitment activities, which form was developed iteratively with input from beyond the 
network.  Cognizant of the longstanding complaints about human research consent forms,45 efforts were 
made to ensure brevity and clarity within the context of a broad consent model (see Declaration 7).  Such a 
model was felt to be in keeping with common practice, and the sustainability needs of the undertaking.  The 
elements of the CCF are identified in Table 1 below.  Where donors have voluntarily affirmed the 
declarations noted therein, EBiSC can be satisfied with the provenance of the material.  Of course, caution is 
warranted; EBiSC cannot guarantee that potential donors have complete understanding, particularly given 
that it is once-removed from the donors, who are recruited by the iPSC Centres and their extended networks 
(though these members have received training around conveying the nature and ambitions of EBiSC, 
assessing understanding, and fielding questions).46  Nonetheless, until some data is generated as a result of 
usage, it is impossible to say what potential donors think they are consenting to.  As an aspect of its 
standard-setting agenda, EBiSC expects that the CCF may be taken up by other recruiters, but to justify this, 
it is probably incumbent on EBiSC (or rather its Legacy Entity) to check-in with donors with respect to their 
ongoing understanding and expectations.47 
 
Table 1: Common Consent Form 
1. I confirm that I have read, considered, and understood the [Recruiter] Information Sheet dated … and the 
CIP dated ...   
2. I have had the opportunity to ask questions, and have had them answered to my satisfaction.   
3. My donation is voluntarily given. 
                                                          
44  Stacey et al., note 42; H Gottweiss and G Lauss, ‘Biobank Governance in the Post-Genomic Age’ (2010) 7 
Personalized Medicine 187-195; J Kaye, ‘From single biobanks to international networks: Developing e-governance’ 
(2011) 130 Human Genetics 377-382. 
45  See I Albalan, M Doyle et al., ‘The Evolution of Consent Forms for Research: A Quarter Century of Changes’ 
(2010) 32 Ethics & Human Res 7, and M Paasche-Orlow, H Taylor et al., ‘Readability Standards for Informed-Consent 
Forms as Compared with Actual Readability’ (2003) 348 N Engl J Med 721. 
46  On this point, see B Palmer, E Cassidy et al., ‘Effective Use of Consent Forms and Interactive Questions in the 
Consent Process’ (2008) 30 Ethics & Human Res 8. 
47  In this regard, it might be observed that the commercial nature of EBiSC is not emphasised by the declarations 
in Table 1.  While, the commercial nature of EBiSC, together with its sustainability ambitions, are made clear in the 
Common Information Pamphlet (CIP), commercial use and exploitation is one of the primary concerns of research and 
biobank participants.  As such, one might question whether EBiSC has done enough in these publicly-facing documents 
to ensure that potential donors understand the implications of their participation.  It should also be acknowledged that 
feedback of information, which is refused in Declaration 8, remains a live issue, and any change to researchers’ 
obligations that might be mandated by law would have to be reflected in a revised CCF and CIP. For more on this, see R 
Brownsword, ‘New Genetic Tests, New Research Findings: Do Patients and Participants have a Right to Know – and Do 
They have a Right Not to Know?’ (2016) 8 Law Innovation Tech 247. 
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4. I understand and agree that material and information derived from the samples I donate may be stored 
indefinitely, and made available to researchers around the world.  
5. I agree that DNA, full genome sequencing data, and other genetic information originating in the samples 
may be collected, stored and made available to researchers.    
6. I give permission for health professionals to make relevant portions of my medical records available to 
researchers. 
7. I understand that any samples I donate, and material and information derived from them, may be used in 
future research, without any need for further consent by me.    
8. I understand that unless required by national law, no information gained from tests conducted on the 
donated samples, or on iPS cells derived from them, will be communicated to me.   
9. I understand that I will receive no financial gain, research results, health benefit, or any other immediate 
benefit, as a consequence of my donation of tissue.   
10. I understand that I am free to withdraw from the project at any time, and that withdrawal means: (a) any 
iPS cells that have already been created from the donated samples will not be destroyed, and information 
about them will be retained; (b) any original donated samples that are stored, or any portion of them 
that has not been consumed, will be returned or destroyed at my request; (c) information that I have 
provided, or that with my consent has been obtained from my medical records, will be deleted and not 
used for research or any other purpose; (d) I retract my consent to any future access to my records. 
11. I agree to give samples of my blood or other tissue to [iPSC Centre]. 
12. I [am / am not] willing to be re-contacted at any time in the future in connection with this or any other 
such project.  
 
EBiSC has also developed a Material Deposit Agreement (MDA), which addresses both provenance and 
quality, touching on some technical matters.  Under the MDA, depositors explicitly agree to: 
 
• supply the stipulated quantity of original material to EBiSC; 
• provide the original data associated with the material after having taken measures to ensure no 
personal identifiable information or keys to same are transferred; 
• provide evidence that (a) the material was generated in accordance with all necessary licences from 
applicable authorities, and (b) all necessary and appropriate consents and ethical approvals in 
relation to the material are in place, or, if no specific consent has been obtained, that approval of 
inclusion in an international bank such as EBiSC has been granted by a Research Ethics Committee; 
• provide information relating to any obligations to third parties in relation to the material; 
• comply with all deposit procedures, which include completion of the standard EBiSC Biohazard Risk 
Assessment form, and documentation necessary to satisfy health and safety regulatory 
requirements. 
 
For its part, EBiSC agrees to: store the material in accordance with international banking standards;48 only 
grant access to the material pursuant to its AUA; implement a communications strategy with potential users; 
                                                          
48  These standards are articulated in part by the OECD Guidelines on Human Biobanks and Genetic Research 
Databases (2009), and the evolving state-of-the-art as found in leading scientific publications.  The Agreement, as 
amended on 1 January 2015, stipulates: 4.5 Each Participant represents and warrants that any Human Samples required 
for use in the Project to be obtained, handled or used by it will be obtained handled or used in accordance with all 
relevant laws and regulations (including national laws and where applicable local ethical guidelines) regarding the 
collection, use, transport and subsequent disposal of human tissue or biological samples and that any ethics committee 
approvals and donor informed consents required will be obtained prior to the commencement of the respective part of 
the Project work.  4.6 Unless otherwise required or prohibited by law, the Participants warrant, to the best of their 
knowledge, that in relation to the performance of this Project Agreement: (a) they provide a safe and healthy 
workplace … ; (b) they do not discriminate against any employees on any ground … [and] they are responsible for 
controlling their own supply chain and that they shall encourage compliance with ethical standards and human rights 
by any subsequent supply of goods and services that are used by the Participants when performing their obligations 
under this Project Agreement. 
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acknowledge the role of depositors, and note the source of material/data used in publications; comply with 
legal or regulatory requirements relating to the material and data;49 and draft an accurate catalogue 
description of resultant iPSC lines.  Once material is received, EBiSC puts it through quality control measures 
agreed within the Consortium and confirmed by its Scientific Advisory Board.50  (The physical material is also 
expanded and characterised at the EBiSC facilities using the most recent reliable techniques.)  Through these 
forms and practices, EBiSC has taken reasonable steps to erect rigorous criteria, both scientific and ethical, 
for inclusion of lines in the bank. 
The second operational challenge is ‘traceability’, which implicates linkage, enclosure and the 
ethically significant concept of privacy.  Linkage refers to the need for good evidence around the origin of the 
sample, the cell-line preparation protocol, and the cell-line storage/maintenance regime.  This demands 
good SOPs directed at minimising (or eliminating) the possibility of misidentification as materials come into 
the bank, and as lines are sent out; it has been noted that “[t]he circulation of poor-quality, misidentified, or 
mycoplasma-infected cell lines would sustain an unacceptable waste of resources and publication of 
misleading information.”51 Enclosure refers to the need to protect the privacy of donors, which is 
guaranteed by Article 8 of the European Convention on Human Rights.52  It demands compliance with 
relevant data management/protection rules aimed at preserving confidentiality of the personal and sensitive 
information associated with samples and related data.53 
Many aspects of this issue are addressed by the MDA, which requires clear evidence from the 
depositor as noted above.  To protect confidentiality, EBiSC allocates a code to individual samples and 
records, keeping all personal details of the donor separate from samples, cell-lines and data, but linked by 
that code.  Researchers do not have access to the personal details, and all information is held in secure 
databases, again in conformity with current international best practice.  Reports or publications are also 
encoded to avoid situations in which the donor’s identity might inadvertently be revealed.  It is made clear 
to all donors, however, through the pre-consent CIP, that it is impossible to guarantee that one’s identity will 
not be traceable through other public data systems.54  It is stipulated, though, that insurance companies and 
employers will not have access to any information held by the bank, and that access by the police will not be 
granted other than under court order.  Under the MDA, both EBiSC and its depositors agree not to disclose 
any confidential information which is not original data provided to it by the other.  Under the Access and 
User Agreement (AUA), users confirm that they will make no attempt to establish the personal identity of 
individual donors from which lines are derived, and they will use banked material or data solely for research 
and in compliance with all applicable laws, regulations and codes, and third party obligations. 
The third operational issue is distribution.  Clear and fair rules are needed, not only to gate-keep 
                                                          
49  Given that the primary EBiSC facility is in the UK, it will have to comply with tissue-handling standards derived 
from the Human Tissue Act 2004, as amended, and its license thereunder, as well as to relevant data-management 
practices imposed under the Data Protection Act 1998, which will be amended in keeping with the new EU General 
Data Protection Regulation, coming into force in 2018. 
50  The criteria for which were negotiated and tested within the Consortium: Harmon, note 43. 
51  Stacey et al., note 42, at 387. 
52  Article 8(1) Everyone has the right to respect for his private and family life, his home and his correspondence. 
Article 8(2) There shall be no interference by a public authority with the exercise of this right except such as is in 
accordance with the law and is necessary in a democratic society in the interests of national security, public safety or 
the economic wellbeing of the country, for the prevention of disorder or crime, for the protection of health or morals, 
or for the protection of the rights and freedoms of others. 
53  These rules will change in 2018 with the EU General Data Protection Regulation.  For more on its implications 
for biobanks, see M Morrison, J Bell, S Harmon et al., ‘The European General Data Protection Regulation: Challenges 
and Considerations for iPSC Researchers and Biobanks’ (2017) 12 Regen Med 693. 
54  ICTs are such that genetic identity between the donor cells and the iPSC line can, with some effort, be traced, 
not least because of the possibility of reprogramming iPSCs back to their origins such that identification of individuals is 
a possibility: K Aalto-Setӓlӓ, B Conklin, B Lo, ‘Obtaining consent for future research with induced pluripotent cells: 
Opportunities and challenges’ (2009) 7 PLoS Biology e42; B Lo, L Parham et al., ‘Cloning mice and men: Prohibiting the 
use of iPS cells for human reproductive cloning’ (2010) 6 Cell Stem Cell 1. 
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access to the resource, but to promote the resource and thereby realise its social value.  At base, the 
custodian must ensure that only legitimate researchers with appropriate prior scientific review and ethical 
approval gain access to the resource, but that they can do so readily and cost-effectively.  Rules need to be 
standardised for particular types of users, and it has been recommended that material transfer agreements 
should encourage full use of the resource (i.e., refrain from applying serious constraints on research, or from 
establishing reach-through ownership of discoveries on the part of the derivation centre or the bank).  EBiSC 
promotes its resource through its website and a range of other media.  Its AUA states that banked material 
and data can only be used for research purposes, which includes pre-clinical research and development 
activities, activities relating to developing the ability to commercialise a drug substance (including process 
development work), and all activities relating to seeking, obtaining and/or maintaining any regulatory 
approvals from a regulatory authority.  The definition of research purposes excludes the use of material in 
human clinical testing and as therapeutics.  The AUA grants the user and any affiliated entity a non-exclusive, 
royalty-free, worldwide licence to use the material and data for research during the term of the agreement, 
subject to third party obligations.  It also stipulates that the user retains ownership of any intellectual 
property arising out of its research reliant on the material and data and derivatives.  Upon termination or 
expiry of the AUA, the user’s access rights cease, and the user must discontinue its use of the material, 
return or destroy any remaining material, and notify each affiliated entity or subcontractor to whom it has 
given access to the material of the termination or expiry of the AUA.  Absent from the AUA is a warranty on 
the part of the user that it has scientific and ethical review and approval for the research it intends to 
conduct, or any statement as to the social value of its intended research. 
The final operational issue relates to capacity-building (i.e., the development of institutional, 
organisational, managerial, technological, cultural, and individual skills and knowledge).  An entity can only 
develop and innovate if its workforce is properly trained and given opportunities to cross-fertilise their skills 
and knowledge through ongoing training and collaboration.55  EBiSC has undertaken a programme of 
technical training and information-sharing across the Consortium so that its scientific members (in 
particular) are using best practice and technologies in their respective activities.  Indeed, an entire Work 
Package is detailed to providing training, and some of the tasks associated with other Work Packages involve 
identifying and embedding new technologies and establishing systems which will ensure the highest level of 
quality control.  The process has been supplemented by engagement between scientific members and 
potential depositors.  For example, EBiSC has undertaken a number of engagement activities that put EBiSC 
management and facilities personnel together with iPSC Centres, clinical partners (recruiters), and potential 
users.  At these workshops, stakeholders discuss (1) the manner in which donated tissue and associated 
medical data will be used to create iPSC lines and to pursue further research, (2) any concerns the 
stakeholders or their patients may have with the use of donated tissue and data, and (3) national laws and 
regulations which may impact on the sourcing of tissue/data/lines from that jurisdiction. 
All told, ethical governance is intimately connected to practical/scientific operations.  In an effort to 
achieve ethical governance, and to ensure smooth operations, EBiSC has expended significant time and 
resources to develop sensible and ethically-sensitive SOPS and forms in its Phase I activities.  They are not 
perfect, nor can they be viewed as settled, but they probably represent a more robust compliance with this 
RRI-alignment criterion than has been achieved under the first one.  Making its operational forms (e.g., CIP, 
CCF, MDA and AUA) more publicly accessible would go some way to improving the situation under the first 
RRI-alignment criterion.56 
 
iii. Duties, Accountability, Reflection and Anticipation 
 
                                                          
55  T Nchinda, ‘Research Capacity Strengthening in the South’ (2002) 54 Soc Sci Med 1699; A Farazmand, 
‘Innovation in Strategic Human Resource Management: Building Capacity in the Age of Globalization’ (2004) 4 Public 
Org Rev 3. 
56  Indeed, exposing them and soliciting public feedback on these forms would help to generate a better 
understanding of the concerns highlighted in note 47 above, an objective undeniably supportive of RRI. 
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This last RRI-alignment criterion addresses the governance or decision-making framework applicable to the 
resource (i.e., the powers, liabilities and activities of the bank’s custodian as opposed to the documents that 
structure its relations with depositors and users).  RRI imposes both transparency and comprehensibility 
around the constitution of the bank and how it might be altered in the future.  It therefore demands clarity 
around: 
 
• the constituent bodies and function-specific decision-makers (i.e., lines of responsibility for 
accepting deposits, setting technical custodial standards, permitting access to the resource); 
• the recording/reporting of decisions, processes for review/appeal, and consequences for decisions 
taken without proper evidence or with improper motivation; and 
• the processes for and scope of engagement and reflection (i.e., mechanisms by which the bank can 
assess its practices, and through which it might develop further information about its functioning). 
 
As noted above, the EBiSC Agreement and DOW serve as the primary governance framework for Phase I.  
These were negotiated by the Consortium Members with input from the IMI and EFPIA, and they address a 
host of issues, including management, finances, participant liabilities, ownership of intellectual property, 
bank usage rights, and more.  Under them, EBiSC is comprised of research organisations, universities, small 
and medium enterprises, and pharmaceutical companies structured as follows: 
 
• Management: The Project Coordination Team (PCT), which is drawn from Roslin Cells and an EFPIA 
Partner, coordinates the project and manages the emerging entity with support from the Project 
Administration Office, which is provided by ARTTIC.  
 
• EFPIA Group: Six pharmaceutical companies contribute funds and in-kind support to the project, 
with support including scientific and business advice/experience. 
 
• iPSC Centres: Eight centres from academia, small enterprise and the not-for-profit sector, each with 
an established track record in the generation of new iPSC lines, and each with direct connections to 
European clinical and patient groups, undertake donor recruitment and sample collection in 
Belgium, Denmark, Germany, Spain, and the UK. 
 
• iPSC Facilities: The main quality assurance and line-derivation facility, operated by Roslin Cells, is at 
the Babraham Research Campus, England, with a mirror facility at Fraunhofer IBMT, Germany, the 
latter of which is also developing improved SC culture and cryopreservation systems. 
 
• Scientific Group: Members are designing standardised, high quality, cost effective and rapid scientific 
characterisation data for the banked iPSC lines, and the European Cell Culture Collection (ECACC), a 
part of Public Health England, is storing distributable iPSC lines, processing orders via its e-commerce 
platform, and coordinating cell line distribution. 
 
• IT Group: Members are iteratively designing an information management system which allows users 
to submit, search and retrieve a rich collection of data on each banked line. 
 
• Legal and Ethics Group: Members are working to facilitate ethical operation and governance that will 
optimise the utility and longevity of EBiSC. 
 
This represents a dispersed coalition of technical and ethical experts dedicated to recruiting donors from 
multiple jurisdictions (with the number of depositing jurisdictions expected to increase), and delivering 
products worldwide.  All Work Packages have specified duties in pursuit of this, and it is the responsibility of 
the Project Coordination Team (PCT), supported by a Project Administration Office located at ARTTIC, to 
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manage the members toward fulfilment of their deliverables.57 
However, while these groups are identified on the EBiSC webpage, very little of EBiSC’s decisional or 
power structure, SOPs, or forms are discernible through this portal.  The Contact page identifies key 
decision-makers, but no obvious hierarchy or decision tree.  A potential donor or user might therefore have 
unanswered questions like: 
 
• What decisions does the Consortium Board have responsibility for, and what values will it bring to 
bear in making decisions (about, for example, dispersing funds, or accepting depositor material)? 
• How will the Consortium Board, or, alternatively, the Project Coordinator or the Managing Entity, 
assess the quality and ethical foundation of a potential user’s use of the resource? 
• Who is entitled to decide to change EBiSC’s decision-making approaches? 
• If a patently bad decision is made, who is accountable and to what consequence? 
 
In addition, one could argue that, while EBiSC has made a commitment to support only good and ethical 
research, it has not clearly signalled to publics the specifics of what is expected or the rigour by which 
evidence will be scrutinised.  Ultimately, then, there is precious little evidence by which the outside observer 
might evaluate EBiSC with respect to the trust and justice concerns that underlie RRI.58 
As persistently reiterated above, reflexivity sits at the heart of RRI; this allows for experiential 
evolution of the bank, its structures, and its practices, thereby supporting responsiveness to changing 
circumstances.  It has been said that reflexive governance: 
 
… is both about in-parallel partnership in governance in the face of future uncertainty and 
the facilitation of mutual learning for experience over time. It can be seen as ‘… a mode of 
steering that encourages actors to scrutinise and reconsider their underlying assumptions, 
institutional arrangements and practices.’59 
 
In all cases, these characteristics must be relayed and accessible to those within the bank, to those with 
whom the bank has direct dealings, and to the wider world.  Shortcomings in communication are highlighted 
above, but are compounded when it comes to the specifics of ongoing interactions.  EBiSC has done quite 
well with respect to its internal communications, which rely on an EBiSC newsletter to all members, regular 
                                                          
57  A particularly challenging period for the PCT was the 18-month period of EBiSC’s formation and launch and 
‘hot start’, a consequence of which was that tasks which one might have expected to have been pursued linearly were 
in fact developing coincidentally.  For example, the preparation of regulatory and ethical maps of Europe, beginning 
with the partner countries, which would have been most impactful at commencement (or shortly thereafter), were 
instead prepared over the course of Phase I; a delivery date enforced by the combination of EBiSC’s structure and 
funding, and the need to ensure that all valuable tasks were performed with appropriate competence and diligence.  
While the pressures of this were felt most sharply by the PCT, all Work Packages had to respond; the Law and Ethics WP 
faced particular demands as it performed the solicitor-like function of drafting, in dialogue with Consortium members, 
the CIF, CCF, MDA, and AUAs.  
58  Internally, EBiSC has formulated SOPs to encourage standardised interaction and reliance on common 
information that will lead to fair decisions applicable to members.  For example, EBiSC has formalised a procedure for 
commissioning new iPSC lines for its inventory.  Its Budget Allocation Procedure is triggered in response to applications 
by members to the Consortium Board for funds to generate new lines, and it relies on pre-defined evaluative criteria.  
The criteria includes, inter alia, questions around scientific and technological relevance, appropriate expertise, and 
legal/ethical compliance.  The legal/ethical questions include: Is there evidence of relevant legal agreements in place?  
Is there evidence of informed consent which allows for commercial research associated with the samples?  Is there 
freedom to operate as regards IPR aspects to the lines proposed?  Has there been an acceptance of use of EBiSC 
MDA/AUA?  Is any clarification needed with regard to any restrictions or obligations in conjunction with funding from 
other parties impacting the use of lines? 
59  G Laurie, ‘Reflexive Governance in Biobanking: On the value of policy led approaches and the need to 
recognise the limits of law’ (2011) 130 Hum Genet 347, at 351. 
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Work Package Leader meetings, and the critically important General Assembly Meetings, to which funders 
and others are invited.  In short, EBiSC has established a series of platforms through which it can exercise 
internal reflexivity (i.e., through which it can collect experiential evidence from its members and collate that 
into something that can be discussed at multiple levels).  This is facilitated by the availability of the Scientific 
Advisory Board and Ethics Advisory Board to field inquiries on an ad hoc basis.  EBiSC is also in constant 
contact with potential users so as to identify the types of cell lines that the bank should be developing, and it 
deployed a web-based questionnaire to facilitate such information-gathering.  However, with respect to 
broader and inclusive (external) engagement, EBiSC has not yet taken measures to exemplify a step-increase 
in standards applicable to international good governance best practice.  More will need to be done to 
facilitate public engagement. 
 
 iv. EBiSC and the RRI Criteria Summed Up 
 
What can one conclude from the above assessment of EBiSC’s Phase I activities?  Certainly, it has achieved a 
lot, and, one can see that it has been sensitive to the need for ethically-grounded governance processes and 
forms.  It has also gone to some lengths to engage proactively and persistently across the Consortium, and 
with its primary external (expert) stakeholders.  Nonetheless, EBiSC’s Phase I achievements are probably 
best characterised as representing uneven and imperfect compliance with the project-level RRI criteria 
identified in Section 3 above. 
Most significantly, its website – which represents its main public communication tool – is neither 
complete nor dynamic.  With respect to the former, it does not contain a clear and explicit ethical 
justification of its aims.  Thus, it has probably not sufficiently conveyed its social utility, or the ‘good 
outcomes’ it is intending to achieve.  Additionally, it fails to provide public versions of the key governing 
instruments (i.e., the Agreement, DOW, CIP, CCF, MDA and AUA), which means that people cannot easily 
know or assess its structures and decision-making processes.  With respect to the latter, dynamism, it caters 
to depositors and users, but fails entirely to provide a means for subsequent donor contact or public 
engagement.  There are no means by which to open a discourse, to explore issues contained in the CCF, or to 
air concerns about the commercial elements of the undertaking.  Presumably any concerns about such 
would have been assuaged at the stage of consent (in order to secure participation), but processes for re-
engagement might be warranted, and they do not yet exist.60 
Of course, imperfect reflection of RRI at this stage might be expected; Phase I was always seen as a 
‘bedding in’ period during which conversations across the Consortium would lead to the design, in Phase II, 
of the Legacy Entity, which would be governed outside the Agreement and DOW.  It is at that stage that the 
bank might expect to be more stringently assessed against the RRI criteria.  In short, the largely un-publicised 
structure that currently exists is not expected to endure unaltered into the Legacy Entity.  This begs the 
question: What follows? 
 
5. RRI and EBiSC Phase II: What Way Forward? 
 
While the above ‘what follows’ question will be tackled in EBiSC Phase II, the members of the PCT and the 
Law and Ethics WP, in conversation with other Members, have turned their minds to this creative task.  
Identifying future governance objectives and forms for the Legacy Entity must take into account how EBiSc 
will consider the risks of research which it supports, how EBiSC will cooperate with stakeholders, and how it 
will expose itself to independent scrutiny and critique.61 
While much biobank operational guidance is grounded firmly in the concept of ‘risk’, risks to biobank 
donors, depositors, and users are rather small, and of a different nature and degree than that associated 
                                                          
60  A more dynamic and interactive platform was recommended at the outset, but was ultimately abandoned as 
exceeding the budgetary allocation for the non-scientific activities. 
61  Stahl, note 17.  It must be acknowledged that RRI presents a design challenge that is empirical: J Gardner and C 
Wiliams, ‘Responsible Research and Innovation: A Manifesto for Empirical Ethics?’ (2015) 10 Clinical Ethics 5. 
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with traditional clinical research.  Personal data release and physical damage are examples of risks, but the 
degree of physical harm is low-to-nil, and the harm from data-release is medium-to-low, depending on the 
specific context.62  Thus, it has been argued that a solidarity-based approach (as opposed to a strongly risk 
and autonomy-based approach) to biobank governance is warranted,63 and that: 
 
A biobank reflective of [solidarity] would pursue assisting others as its main research goal; 
that is, the main activity of the biobank would always have to be research aiming to 
improve health of individuals or populations (or comparable, other-directed goals). In 
addition, transparency towards participants is required about how the goal of improving 
the health of individuals and populations relates to commercial goals.64 
 
At present, and consistent with other biobanks, EBiSC has focused on risk and adopted a broad consent 
model, with limitations relating to withdrawal.  Given the above, an evolution might be warranted, though 
again, it would need to be extensively discussed within and beyond the Consortium.  To date three 
interrelated governance objectives have been raised within EBiSC, at least preliminarily: ‘alignment’; 
‘experiential design’; and ‘transparency’. 
Alignment refers to the ambition of having EBiSC’s practical goals reflected in its (future) governance 
structure.  Some of those practical goals include: (1) the inspiration and preservation of public trust, which 
necessitates ongoing attention to operational issues such as provenance of material, harmonisation of 
standards and practices, and transparency of decision-making and expectations around use; and (2) 
innovative approaches to sustainability and accessibility, which necessitates a sound business model, 
minimal barriers to use, and reduced encumbrances on cell-lines made available through the bank.  The 
second objective – experiential design – relates directly to reflexivity as articulated in Section 3 above.  The 
expectation is that EBiSC will develop evidence around its functioning and draw on the expertise that its 
members have to formulate solutions in a responsive way to operational demands/needs.  Of course, 
moving forward, this will demand a built-in mechanism so that incremental change can be realised.  This, in 
turn, requires that governance structures/mechanisms are proportionate (as opposed to burdensome) and 
are applicable to all members.  The final governance objective is that of transparency.  Depositors, users, and 
publics should have clear and unambiguous information not only about the cell-lines in the resource, but 
also about how decisions are made, and by whom.  One can see, then, that some of the existing 
shortcomings (from an RRI perspective) are already being discussed. 
I contend that these objectives impose on EBiSC two associated duties.  The first, and one that has 
been advocated elsewhere,65 is to agree on a set of values that will form a backdrop to EBiSC.  They serve as 
a signal to stakeholders and publics about what will inform actions and decisions.  The second is to adopt an 
Ethics and Governance Framework (EGF) that publics can access, understand, and use as a benchmark to 
assess the Legacy Entity. 
Given EBiSC’s ambition to advance socially valuable scientific outcomes, and good science and 
corporate citizenship, a range of values seems pertinent.  Empirical research in the regenerative medicine 
setting has already uncovered a number of values in three broad categories (i.e., values that inform the 
researcher’s social vision and outcomes; values that inform the project’s approach to governance; values 
                                                          
62  European Commission Expert Group on Dealing with Ethical and Regulatory Challenges of International 
Biobank Research, Biobanks for Europe: A Challenge for Governance (Brussels: EC, 2012).  And the risk of improper data 
release will be further minimised as actors take steps to comply with the new General Data Protection Regulation 2018. 
63  S Harmon and A McMahon, ‘Banking (on) the Brain: From Consent to Authorisation and the Transformative 
Potential of Solidarity’ (2014) 22 Med Law Rev 572. 
64  B Prainsack and A Buyx, ‘A Solidarity-Based Approach to the Governance of Research Biobanks’ (2013) 21 Med 
Law Rev 71, at 77. 
65  Ibid, at 84. 
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that resource operators expect users to hold and advance).66 Obviously, these categories are not watertight, 
and values relevant to one category may be relevant others. 
With respect to values applicable to social vision, and the development and provision of service, the 
notions of ‘wellbeing’, ‘solidarity’, ‘dignity’, ‘justice’, and ‘autonomy’ are all important.  On wellbeing, EBiSC 
must acknowledge that community wellbeing and productivity depends on human health; it is important to 
protect life, health, and wellness, both physical and psychological, and to support actions which facilitate 
quality of life.  On solidarity, EBiSC must recognise the importance of interconnectedness, emotional ties to 
others, and the common good, and assume a general obligation to advance the wellbeing of the vulnerable.  
The value of research is therefore often sensibly measured by how well it aligns with society’s problems and 
generates social benefits, an idea at the heart of RRI.  On dignity, EBiSC must recognise the importance of 
respecting people; thus, while it properly espouses the value of knowledge generated within moral bounds, 
and the associated propriety of pushing boundaries and being creative, it must acknowledge the need to 
balance the research imperative with other values, always being careful not to instrumentalise people.  On 
justice, EBiSC must realise equality and equity through its operation, acknowledging the need to share fairly 
the benefits of research.  On autonomy, EBiSC must understand the desire of individuals and communities to 
exercise free will, and so create space for people to make decisions about themselves and for themselves, 
according to their values.  This not only demands that stakeholders be given adequate information so they 
can weigh options and make reasonably informed decisions, and be satisfied that agents will take reasonable 
steps to protect their personal information, but also empowering them, and work around dynamic consent 
may be useful here.67 
With respect to values that inform approaches to governance of the resource, ‘transparency’, 
‘engagement’ and ‘reflexivity’ are important, and are highlighted by RRI.  Adherence to these values 
combined suggests that EBiSC must aim to model comprehensible and open decision-making structures, and 
to encourage information-sharing in multiple directions by designing rational structures to manage the 
resource, multi-directional communication strategies, and undertake periodic reviews of its governance 
practices to ensure that they are fit for purpose.  Engagement emphasises the function of partnership and 
information-sharing across multiple communities, while reflexivity emphasises the need for governance 
practices and strategies to evolve through iterative review, taking into account the views and experiences of 
its members and stakeholders. 
Finally, with respect to values that depositors and users might be expected to advance, many of 
those identified above are again implicated.  But to them one might add ‘integrity’, ‘excellence’, and ‘safety’.  
This means that EBiSC will have to take steps to ensure that the researchers with whom it interacts are 
honest with and about patients and subjects, and with research data, and that they must sensitively balance 
the responsibility of advancing human knowledge with that of benefitting humankind, and ensuring that 
donors and patients are not put at undue risk. 
Many of these values are implicated by the notion of RRI, and many of them are already advanced 
by EBiSC through its processes and operations (and its initial attempt to meet the RRI criteria).  But by 
explicitly naming and highlighting these values, EBiSC would signal its commitment to supporting only 
virtuous researchers conducting research with some potential to alleviate human suffering.  Operationalising 
these values implicates the second duty noted above – designing a suitable EGF that facilitates sustainability.  
The EGF could erect structures and processes that are clearly consistent with, and explicitly targeted at, 
                                                          
66  See S Harmon, ‘Regulation of Stem Cell and Regenerative Science: Stakeholder Opinions, Plurality and Actor 
Space in the Argentine Social/Science Setting’ (2010) 2 Law, Innovation & Technology 95, and S Harmon, Opinion 
4:2010: Guiding Values: Argentine Stem Cell Research and Regenerative Medicine, for the Argentine Ministry of Science 
& Technology, at http://www.scriptcentre.ed.ac.uk/opinions. 
67  K Steinsbekk, B Myskja and B Solberg, ‘Broad consent versus dynamic consent in biobank research: Is passive 
participation an ethical problem?’ (2013) 21 European J Human Genetics 897; D Stein and S Terry, ‘Reforming biobank 
consent policy: a necessary move away from broad consent toward dynamic consent’ (2013) 17 Genetic Testing and 
Molecular Biomarkers 855; J Kaye, E Whitley et al., ‘Dynamic Consent: A patient interface for twenty-first century 
research networks’ (2015) 23 European J Human Genetics 141. 
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these values.  Some of the specific matters that an EGF would address are outlined above (i.e., constituent 
bodies, decisional authority, communication strategy and platform, structures and practices supportive of 
engagement, etc.), but the interaction between research and commerce, access by commercial entities, and 
the need for the biobank itself to be sustainable would all have to be explicitly addressed. 
 
6. Conclusions 
 
Good governance is enacted by many parties, including those who are themselves governed.  Thus biobank 
operators who are subject to external regulation also construct the governance setting applicable to them.  
In Europe, the good governance of research and innovation is presently influenced by the regulatory notion 
of RRI, a notion which has implications not only for regulators (and funders), but also for research 
institutions and researchers – regulatees.  Although the majority of existing and emerging biobanks fail to 
adopt a prospective governance strategy,68 the obligations imposed by RRI (which itself is surely tied to the 
ideas of legitimacy and transparency) make clear that this is not an acceptable state of affairs.  The 
regulatory expectation is that actors will be communicative, undertakings will be structured to ensure the 
ethicality of their operations, and decisions will be evidence-based, informed by dialogue, and anticipatory in 
scope.  Given EBiSC’s multiple ambitions (one of which is to serve as a flagship enterprise and standard-
setter for Europe and beyond), it is incumbent on EBiSC to design in Phase II a governance framework that is 
robustly supportive of RRI (i.e., comprehensible, reflective of the above values and justice characteristics, 
and conveyed to the public in an accessible manner).  This must be achieved in the face of changing legal 
standards and must not impose undue burdens on those trying to advance knowledge (i.e., depositors to 
and users of the resource).  This is by no means an easy task.  Presumably, the not-for-profit Legacy Entity 
will be structured like a corporation, but, as is well recognised in the life sciences and public resource setting, 
something more than a straight-up corporate structure is warranted if justifiable trust is to be maintained.69  
Attention must be paid to the ‘stewardship’ role of the body.  EBiSC Phase I has represented a sound if 
imperfect launch-pad, but important work lies ahead in Phase II if EBiSC is to meet the promises made 
through its founding. 
                                                          
68  A Cambon-Thompson, E Rial-Sebbag and B Knoppers, ‘Trends in Ethical and Legal Frameworks for the use of 
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